Brief: Heidelberg Pharma Announces First Patient Dosed With Antibody Targeted Amanitin Conjugate HDP-101

Heidelberg Pharma AG

15/02/2022 06:15

Feb 15 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * ANNOUNCES FIRST PATIENT DOSED WITH ANTIBODY TARGETED
AMANITIN
CONJUGATE HDP-101 IN MULTIPLE MYELOMA
    * ANNOUNCED THAT FIRST PATIENT HAS BEEN DOSED WITH HDP-101
IN A
PHASE I/IIA STUDY AT WINSHIP CANCER INSTITUTE OF EMORY
UNIVERSITY, ATLANTA, GA, USA

Source text for Eikon:  ID:nEQ9c2XTxa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))